Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.52 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2269896 | 0.90 | TDP1 (0.58) | TDP1NR1H4MEN1KMT2ALMNA | |
| SCHEMBL2275467 | 0.88 | CYP2C9 (0.63) | TDP1NR1H4MEN1KMT2AMAPT | |
| SCHEMBL2291001 | 0.86 | NR1H4 (0.62) | TDP1NR1H4MEN1KMT2ARAB9A | |
| SCHEMBL2271588 | 0.86 | SERPINE1 (0.64) | TDP1NR1H4MEN1KMT2AMAPT | |
| SCHEMBL2273349 | 0.85 | MEN1 (0.61) | MEN1KMT2ARAB9ACYP2C9CYP2C19 | |
| SCHEMBL2271007 | 0.85 | MEN1 (0.69) | NR1H4MEN1KMT2AMAPTSERPINE1 | |
| SCHEMBL2274217 | 0.85 | CYP2C9 (0.57) | TDP1NR1H4MEN1KMT2ASERPINE1 | |
| SCHEMBL2270621 | 0.84 | GALK1 (0.68) | TDP1NR1H4RAB9ASERPINE1HPSE | |
| SCHEMBL2273044 | 0.84 | CYP2C9 (0.61) | TDP1NR1H4MEN1KMT2AMAPT | |
| SCHEMBL2276745 | 0.84 | SERPINE1 (0.65) | TDP1NR1H4MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | TDP1 3823/4885NR1H4 2482/4885MEN1 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.